UK medical device maker Belluscura expects 20% tariff on products sold in US

ReutersApr 16, 2025 7:20 AM

April 16 (Reuters) - British medical device maker Belluscura BELLB.L said on Wednesday that its products sold in the United States would face tariff of up to 20% and that the company was evaluating how it could cut down tariff and production costs in the long term.

The company, which focuses on developing portable oxygen technology, also announced that its finance chief, Simon Neicheril, had stepped down.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

TradingKey - Intel Corporation (NASDAQ: INTC) and Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) are two companies that play crucial roles in the semiconductor market; however, they each have completely different business models.

Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

TradingKey - Since April, the precious metals market has continued the weakness seen in March. Spot gold recorded a cumulative decline of nearly 2% in April, while spot silver briefly fell below the $70 mark.

Is SanDisk the Hidden Gem of the AI Boom in 2026? Discover the Potential Risks and Rewards.

TradingKey - SanDisk (SNDK) now represents not just a name for many consumers, but also an investment play on one of the fastest-growing sectors in technology – Artificial Intelligence.

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

TradingKey - On April 29 (ET), Microsoft (MSFT) released its Q3 FY2026 results after the bell. Both revenue and profit exceeded expectations, with Azure growth returning to 40% and annualized AI revenue surpassing $37 billion. Despite this, shares fell more than 3% in after-hours trading and ended t

$11.4 Billion Revenue Vs. 1.75 Trillion Valuation: Can Starlink Support SpaceX IPO?

TradingKey - On April 14, The Information disclosed a set of unpublished financial data: Starlink's satellite internet business revenue grew 50% year-over-year in 2025 to $11.4 billion, with EBITDA reaching $7.2 billion and an adjusted margin as high as 63%.

Featured Tools